Methodology

Study design
> A total sample of 352 US-English speaking PM women aged 40-65 years was recruited into a multi-center, observational study. The sample comprised three samples:
-A 'side effects' sample (n=202) of PM women who were experiencing breast pain and/or vaginal bleeding side effects due to EPT for at least two days in the previous four weeks;
-A 'control' sample (n=75) of PM women taking EPT, but experiencing no side effects;
-An 'untreated' sample (n=75) of PM women not taking EPT and experiencing vasomotor symptoms (e.g. hot flashes for at least two days during the previous four weeks).
Assessments and administration
> The MENQOL comprises 29 items assessing vasomotor symptoms (3 items), psychosocial functioning (7 items), physical functioning (16 items) and sexual functioning (3 items). Employing a four-week recall period, items are rated on a 0-7 numeric rating scale (NRS) ranging from 'not experiencing the symptom' to 'experiencing the symptom and extremely bothered'. Scores are converted to an eight-point scale (1-8) with higher scores indicating greater bother.
> The EQ-5D-5L descriptive system assesses five dimensions of HRQoL, with each dimension assessed by a single item: mobility, self-care, ability to complete usual activities, pain/discomfort, and anxiety/depression. Responses are scored on a five-point verbal descriptor response scale, with higher scores indicating more problems. Participants also rate their overall health on a Visual Analogue Scale (VAS) of 0 (worst health you can imagine) to 100 (best health you can imagine).
> Each assessment was completed at baseline (Visit 1) by all samples and again at week four (Visit 2) by the side effects sample only (the remaining samples only completed baseline assessments).
> In addition to the above assessments the participants also completed daily diary assessments (eDiaries) of breast pain and tenderness (BPT-DD) [3] and vaginal bleeding and spotting (VBS-DD) [4] , a breast sensationsspecific impact questionnaire (BSIQ) [3] , a vaginal bleeding-specific impact questionnaire (PMBIQ) [4] , the Menopausal Symptoms Treatment Satisfaction Questionnaire (MS-TSQ) [5] , the Menopause Rating Scale (MRS) [6] and two Patient-Global Impression of Severity (PGI-S) items. These assessments were not used in the crosswalk analyses and so are not presented here apart from the MRS data which is provided to characterize the samples [8] .
Analyses
> Derivation of EQ-5D-5L utility values
− EQ-5D-5L utility values were derived using published EQ-5D-5L value sets for the US general population created from the EQ-5D-3L using the crosswalk link function, which were estimated based on time-trade off (TTO) valuation techniques [7] .
> Crosswalk methodology
− The crosswalk analysis estimated the relationship between the EQ-5D-5L utility values and MENQOL total scores using regression modelling, where the MENQOL total score was used as a predictor (independent variable) and the EQ-5D-5L estimated utility value as the outcome variable (dependent variable).
− Three regression analyses were conducted using data from Visit 1 and Visit 2, where:  The MENQOL total score was treated as a continuous variable;
 The MENQOL total score was treated as a categorical variable;
 The MENQOL total score data and EQ-5D-5L were averaged over time to have only one observation per subject.
− The first two analyses used repeated-measures model regression (RMM). The RMM model where the MENQOL total score was treated as categorical variable was used as a sensitivity analysis to support linearity assumption of the RMM model where the MENQOL total score was treated as a continuous variable.
− In the third analysis, Ordinary Least-Square regression (OLS) modelling was conducted using averaged MENQOL and EQ-5D-5L data.
− Goodness-of-fit of the OLS model was assessed using the root mean square error (RMSE), R2, correlations and p-values.
− Means and standard deviations (SD) are presented for the MENQOL and EQ-5D-5L derived utility values to compare the spread of the utility values derived from the MENQOL and EQ-5D-5L, by sample.
Conclusion
> This study involved performing a crosswalk to support conversion of MENQOL scores to EQ-5D-5L derived health utility values for group-level analyses of utilities in PM women.
> The results provide evidence that the MENQOL derived utility values presented here are appropriate to use in future studies of PM women in the US.
Results
> Demographic characteristics
− The sample consisted of 352 PM women: n=202 in the side effects sample (n=36 vaginal bleeding/spotting only, n=110 breast pain only, n=56 both side effects); n=75 control sample; and n=75 untreated sample (Table 1) .
− Mean age of the sample was 53.7 years (± 6.6 years).
− The majority of the sample were Caucasian (79.3%, n=279), and Non-Hispanic or Latino (90.6%, n=319) and a high proportion of participants were educated to college/university level (30.4%, n=107). Quality of completion was extremely high with no missing data for either the MENQOL or EQ-5D-5L. (Figure 3 ).
> Conversely, most participants in the control sample (48.0%, n=36) reported experiencing none or minimal menopausal symptoms, as expected (score 0-4). Participants in the side effects sample were spread fairly evenly across the four severity categories. (n=74) not included in the analysis due to incomplete data on the MENQOL and EQ-5D-5L.
> The crosswalk analysis from the RMM model with the MENQOL as a continuous variable showed a sizeable and significant correlation between the MENQOL and EQ-5D-5L (-0.589; p<0.001), with a relationship of the EQ-5D-5L utility value = 0.992-0.042 x MENQOL.
> When OLS was performed using averaged MENQOL data, results were similar to those where the MENQOL was treated as a continuous variable. Goodness-of-fit was moderate (R 2 =0.347; RMSE=0.093).
> A robust linear relationship was found between the MENQOL and EQ-5D-5L scores, with an increase in score on the MENQOL resulting in a decrease in score on the EQ-5D-5L ( Figure 5 ).
-Comparison of results between the model with the MENQOL as a continuous predictor and the model using the MENQOL as a categorical predictor supported the appropriateness of a linear approximation.
-There was a general similarity between the repeated-measures mixed model and the linear regression.
-The repeated measures model had a slope of -0.042 and intercept of 0.992, while the OLS model using averaged data estimated a slope of -0.045 and an intercept of 1.002, respectively. > Using repeated-measures mixed models, participants in the control sample had significantly higher utility values on the EQ-5D-5L and MENQOL compared to participants in the side effects and untreated samples (p<0.001).
− Thus, there was a logical pattern of utility values, with participants in the control sample expected to have highest utility values given that they were taking EPT and not experiencing side effects. 
